All News

AAD 2025. Guttman, among the world's foremost researchers in dermatology, toplined how far the field has come in her "Hot Topics" presentation on the final day of the 2025 AAD.

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

Data on delgocitinib from the DELTA development program highlight efficacy of the topical JAK inhibitor for treatment of chronic hand eczema.

JiaDe Yu, MD, shares key takeaways from his presentation on pediatric allergic contact dermatitis.

Brian S. Kim, MD, a worldwide leader in research into itch and other skin conditions, says the safety profile and ease of use of new treatments for AD mean primary care clinicians should definitely consider prescribing them.

Data on zabalafin hydrogel topical therapy may offer a single, comprehensive approach to manage AD across multiple disease stages.

Daniel Butler, MD, discusses a more complex definition of immunosenescence, and the interplay between aging and itch-related conditions.

Benjamin Ungar, MD, explains the phenotypic and molecular manifestations of Rosacea, and the work still needed to develop targeted treatments.

Butler addresses how primary care can help manage the burdens of itch in their older patients and offers pearls for consulting and referring to dermatology.

AAD 2025. Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial.

Benjamin Ungar, MD, discusses his presentation at AAD 2025 covering advances and updates about rosacea and seborrheic dermatitis.

Dupilumab was associated with the highest drug survival in monotherapy with nearly 90% of study participants remaining on treatment at both 12 and 24 months.

AAD 2025: In a post hoc analysis of the STREAM-AD Phase 2b study, 63% of patients with AD maintained itch reduction even after stopping amlitelimab use.

AAD 2025. Peter Lio, MD, from the Feinberg School of Medicine in Chicago, says, skip the elimination diet because food is rarely a cause of atopic dermatitis.

Data from the TRuE-PN trial program were presented at the 2025 American Academy of Dermatology Annual Meeting in Orlando, offering important insights into potential new therapeutic options for this debilitating condition.

AAD 2025: The IGNITE study of the OX40 inhibitor included adults previously treated with a biologic or systemic JAK inhibitor, according to Amgen and Kyowa Kirin.

Icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor, which is implicated in multiple inflammatory conditions including plaque psoriasis.

AAD 2025: New analysis of the ADORING 3 trial showed tapinarof maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.